Market capitalization | $83.47m |
Enterprise Value | $-24.80m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.38 |
EV/Sales (TTM) EV/Sales | -0.77 |
P/S ratio (TTM) P/S ratio | 2.61 |
P/B ratio (TTM) P/B ratio | 0.62 |
Revenue growth (TTM) Revenue growth | 2.72% |
Revenue (TTM) Revenue | $32.02m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
6 Analysts have issued a Aclaris Therapeutics, Inc. forecast:
6 Analysts have issued a Aclaris Therapeutics, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 32 32 |
3%
3%
|
|
Gross Profit | 21 21 |
22%
22%
|
|
EBITDA | -68 -68 |
33%
33%
|
EBIT (Operating Income) EBIT | -69 -69 |
33%
33%
|
Net Profit | -59 -59 |
44%
44%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
Head office | United States |
CEO | Neal Walker |
Employees | 91 |
Founded | 2012 |
Website | www.aclaristx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.